অস্ট্রিয়া -
জার্মান -
AGES (Agentur für Gesundheit und Ernährungssicherheit)
lapatinib teva 250 mg filmtabletten
ratiopharm arzneimittel vertriebs-gmbh - lapatinibditosilat monohydrat -
জার্মানি -
জার্মান -
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
erlotinib zentiva 100 mg filmtabletten
orifarm gmbh - geschäftsanschrift - (3237116) - erlotinibhydrochlorid - filmtablette - 100 mg - teil 1 - filmtablette; erlotinibhydrochlorid (32273) 109,29 milligramm
জার্মানি -
জার্মান -
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
erlotinib zentiva 150 mg filmtabletten
orifarm gmbh - geschäftsanschrift - (3237116) - erlotinibhydrochlorid - filmtablette - 150 mg - teil 1 - filmtablette; erlotinibhydrochlorid (32273) 163,94 milligramm
সুইজারল্যান্ড -
জার্মান -
Swissmedic (Swiss Agency for Therapeutic Products)
lorviqua 25 mg filmtabletten
pfizer ag - lorlatinibum - filmtabletten - lorlatinibum 25 mg, cellulosum microcristallinum, calcii hydrogenophosphas dihydricus, carboxymethylamylum natricum a corresp. natrium 0.315 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 1.575 mg, macrogolum 4000, triacetinum, e 171, e 172 (nigrum), e 172 (rubrum), pro compresso obducto. - nicht kleinzelliges lungenkarzinom (non small cell lung cancer, nsclc) - synthetika
সুইজারল্যান্ড -
জার্মান -
Swissmedic (Swiss Agency for Therapeutic Products)
lorviqua 100 mg filmtabletten
pfizer ag - lorlatinibum - filmtabletten - lorlatinibum 100 mg, cellulosum microcristallinum, calcii hydrogenophosphas dihydricus, carboxymethylamylum natricum a corresp. natrium 0.84 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 4.2 mg, macrogolum 4000, triacetinum, e 171, e 172 (nigrum), e 172 (rubrum), pro compresso obducto. - nicht kleinzelliges lungenkarzinom (non small cell lung cancer, nsclc) - synthetika
সুইজারল্যান্ড -
জার্মান -
Swissmedic (Swiss Agency for Therapeutic Products)
tyverb filmtabletten
novartis pharma schweiz ag - lapatinibum - filmtabletten - lapatinibum 250 mg ut lapatinibi ditosilas monohydricus 405 mg, cellulosum microcristallinum, povidonum k 30, carboxymethylamylum natricum a, magnesii stearas, Überzug: hypromellosum, macrogolum 400, polysorbatum 80, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto, natrium 2.82 mg. - zytostatikum - synthetika
সুইজারল্যান্ড -
জার্মান -
Swissmedic (Swiss Agency for Therapeutic Products)
tarceva 25 mg filmtabletten
roche pharma (schweiz) ag - erlotinibum - filmtabletten - erlotinibum 25 mg zu erlotinibi hydrochloridum 27.32 mg, lactosum monohydricum 27.43 mg, cellulosum microcristallinum, carboxymethylamylum natricum ein und natrii laurilsulfas endwerte. natrium 2 mg, magnesium stearas, Überzug: hypromellosum, hydroxypropylcellulosum, macrogolum 400, e 171, für compresso dunst. - zytostatikum - synthetika
সুইজারল্যান্ড -
জার্মান -
Swissmedic (Swiss Agency for Therapeutic Products)
tarceva 100 mg filmtabletten
roche pharma (schweiz) ag - erlotinibum - filmtabletten - erlotinibum 100 mg zu erlotinibi hydrochloridum 109.29 mg, lactosum monohydricum 69.21 mg, cellulosum microcristallinum, carboxymethylamylum natricum ein und natrii laurilsulfas endwerte. natrium 6 mg, magnesium stearas, Überzug: hypromellosum, hydroxypropylcellulosum, macrogolum 400, e 171, für compresso dunst. - zytostatikum - synthetika
সুইজারল্যান্ড -
জার্মান -
Swissmedic (Swiss Agency for Therapeutic Products)
tarceva 150 mg filmtabletten
roche pharma (schweiz) ag - erlotinibum - filmtabletten - erlotinibum 150 mg bis erlotinibi hydrochloridum 163.93 mg, lactosum monohydricum 103.82 mg, cellulosum microcristallinum, carboxymethylamylum natricum ein und natrii laurilsulfas endwerte. natrium 9 mg, magnesium stearas, Überzug: hypromellosum, hydroxypropylcellulosum, macrogolum 400, e 171, für compresso dunst. - zytostatikum - synthetika
ইউরোপীয় ইউনিয়ন -
জার্মান -
EMA (European Medicines Agency)
lorviqua
pfizer europe ma eeig - lorlatinib - karzinom, nicht kleinzellige lunge - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.